Exenatide vs Pemvidutide

Molecule comparison

Last updated 2026-05-28 15:46 UTC

Exenatide is a GLP-1 receptor agonist already approved by the FDA to treat type 2 diabetes, available as Byetta or Bydureon. Pemvidutide is a newer GLP-1 and glucagon dual agonist still in development, with no FDA approvals yet for any condition.

AI summary of the sources below.

	Exenatide	Pemvidutide
Mechanism	GLP-1 receptor agonist	GLP-1 and glucagon receptor dual agonist
Status	Approved	Pipeline
Branded products	byetta, bydureon	—

Compare full details on the Exenatide and Pemvidutide pages.